Research programme: acetyl CoA carboxylase 1/2 allosteric inhibitors - Nimbus Therapeutics

Drug Profile

Research programme: acetyl CoA carboxylase 1/2 allosteric inhibitors - Nimbus Therapeutics

Alternative Names: ND-630; ND-646; ND-654

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nimbus Discovery
  • Developer Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Hepatocellular carcinoma; Non-alcoholic steatohepatitis; Non-small cell lung cancer
  • No development reported Diabetes mellitus; Metabolic syndrome

Most Recent Events

  • 28 Jul 2016 Gilead Sciences acquires Acetyl CoA carboxylase 1/2 allosteric inhibitors from Nimbus Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top